http://streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 17 Jun 2026 17:10:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acumen+Pharmaceuticals%2C+++For%3A+Jun+15++Filed+by%3A+Porter+Derrell/26660902.html si-local-file:///var/storage/secattach/20260617/26660902.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acumen+Pharmaceuticals%2C+++For%3A+Jun+15++Filed+by%3A+Porter+Derrell/26660902.html Wed, 17 Jun 2026 17:10:00 -0400 ABOS O.47039291 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acumen+Pharmaceuticals%2C+++For%3A+Jun+15++Filed+by%3A+Porter+Derrell/26660902.html si-local-file:///var/storage/secattach/20260617/26660902.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acumen+Pharmaceuticals%2C+++For%3A+Jun+15++Filed+by%3A+Porter+Derrell/26660902.html Wed, 17 Jun 2026 17:10:00 -0400 ABOS O.47039291 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Acumen+Pharmaceuticals%2C++++++++++++++++Filed+by%3A+Porter+Derrell/26659751.html si-local-file:///var/storage/secattach/20260617/26659751.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Acumen+Pharmaceuticals%2C++++++++++++++++Filed+by%3A+Porter+Derrell/26659751.html Wed, 17 Jun 2026 16:02:00 -0400 ABOS O.47039291 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Acumen+Pharmaceuticals%2C++++++++++++++++Filed+by%3A+Porter+Derrell/26659751.html si-local-file:///var/storage/secattach/20260617/26659751.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Acumen+Pharmaceuticals%2C++++++++++++++++Filed+by%3A+Porter+Derrell/26659751.html Wed, 17 Jun 2026 16:02:00 -0400 ABOS O.47039291 http://www.streetinsider.com/Press+Releases/JCR+Pharmaceuticals+Announces+That+Acumen+Pharmaceuticals+Has+Exercised+its+Exclusive+Option+to+Develop+Therapeutic+Candidates+for+Alzheimer%E2%80%99s+Disease%2C+Enabled+by+J-Brain+Cargo%C2%AE+Technology+Platform/26658824.html <p class="bwalignc"> <i>- Strategic partnership, announced in July 2025, utilizes JCR’s J-Brain Cargo® to develop a novel blood-brain barrier-penetrating therapy targeting a pathological driver of Alzheimer’s disease</i> </p><p class="bwalignc"> <i>- Option exercise puts Acumen’s Enhanced Brain Delivery (EBD™) program on track for IND filing in mid-2027</i> </p> <p> HYOGO, Japan--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fjcrpharm.com%2F&amp;esheet=54556000&amp;newsitemid=20260617134083&amp;lan=en-US&amp;anchor=JCR+Pharmaceuticals+Co.%2C+Ltd.&amp;index=1&amp;md5=fcae3009ac02737d9d40dc50df398793" shape="rect">JCR Pharmaceuticals Co., Ltd.</a> (TSE 4552; JCR), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced that Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) exercised its exclusive option to develop, manufacture, and commercialize, on a global basis, up to two candidates for development http://www.streetinsider.com/Press+Releases/JCR+Pharmaceuticals+Announces+That+Acumen+Pharmaceuticals+Has+Exercised+its+Exclusive+Option+to+Develop+Therapeutic+Candidates+for+Alzheimer%E2%80%99s+Disease%2C+Enabled+by+J-Brain+Cargo%C2%AE+Technology+Platform/26658824.html Wed, 17 Jun 2026 12:30:00 -0400 4552 A.06822034 ABOS O.05105781 O.20026344 O.47039291 http://www.streetinsider.com/Press+Releases/JCR+Pharmaceuticals+Announces+That+Acumen+Pharmaceuticals+Has+Exercised+its+Exclusive+Option+to+Develop+Therapeutic+Candidates+for+Alzheimer%E2%80%99s+Disease%2C+Enabled+by+J-Brain+Cargo%C2%AE+Technology+Platform/26658824.html <p class="bwalignc"> <i>- Strategic partnership, announced in July 2025, utilizes JCR’s J-Brain Cargo® to develop a novel blood-brain barrier-penetrating therapy targeting a pathological driver of Alzheimer’s disease</i> </p><p class="bwalignc"> <i>- Option exercise puts Acumen’s Enhanced Brain Delivery (EBD™) program on track for IND filing in mid-2027</i> </p> <p> HYOGO, Japan--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fjcrpharm.com%2F&amp;esheet=54556000&amp;newsitemid=20260617134083&amp;lan=en-US&amp;anchor=JCR+Pharmaceuticals+Co.%2C+Ltd.&amp;index=1&amp;md5=fcae3009ac02737d9d40dc50df398793" shape="rect">JCR Pharmaceuticals Co., Ltd.</a> (TSE 4552; JCR), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced that Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) exercised its exclusive option to develop, manufacture, and commercialize, on a global basis, up to two candidates for development http://www.streetinsider.com/Press+Releases/JCR+Pharmaceuticals+Announces+That+Acumen+Pharmaceuticals+Has+Exercised+its+Exclusive+Option+to+Develop+Therapeutic+Candidates+for+Alzheimer%E2%80%99s+Disease%2C+Enabled+by+J-Brain+Cargo%C2%AE+Technology+Platform/26658824.html Wed, 17 Jun 2026 12:30:00 -0400 4552 A.06822034 ABOS O.05105781 O.20026344 O.47039291 http://www.streetinsider.com/Press+Releases/JCR+Pharmaceuticals+Announces+That+Acumen+Pharmaceuticals+Has+Exercised+its+Exclusive+Option+to+Develop+Therapeutic+Candidates+for+Alzheimer%E2%80%99s+Disease%2C+Enabled+by+J-Brain+Cargo%C2%AE+Technology+Platform/26658824.html <p class="bwalignc"> <i>- Strategic partnership, announced in July 2025, utilizes JCR’s J-Brain Cargo® to develop a novel blood-brain barrier-penetrating therapy targeting a pathological driver of Alzheimer’s disease</i> </p><p class="bwalignc"> <i>- Option exercise puts Acumen’s Enhanced Brain Delivery (EBD™) program on track for IND filing in mid-2027</i> </p> <p> HYOGO, Japan--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fjcrpharm.com%2F&amp;esheet=54556000&amp;newsitemid=20260617134083&amp;lan=en-US&amp;anchor=JCR+Pharmaceuticals+Co.%2C+Ltd.&amp;index=1&amp;md5=fcae3009ac02737d9d40dc50df398793" shape="rect">JCR Pharmaceuticals Co., Ltd.</a> (TSE 4552; JCR), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced that Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) exercised its exclusive option to develop, manufacture, and commercialize, on a global basis, up to two candidates for development http://www.streetinsider.com/Press+Releases/JCR+Pharmaceuticals+Announces+That+Acumen+Pharmaceuticals+Has+Exercised+its+Exclusive+Option+to+Develop+Therapeutic+Candidates+for+Alzheimer%E2%80%99s+Disease%2C+Enabled+by+J-Brain+Cargo%C2%AE+Technology+Platform/26658824.html Wed, 17 Jun 2026 12:30:00 -0400 4552 A.06822034 ABOS O.05105781 O.20026344 O.47039291 http://www.streetinsider.com/Press+Releases/JCR+Pharmaceuticals+Announces+That+Acumen+Pharmaceuticals+Has+Exercised+its+Exclusive+Option+to+Develop+Therapeutic+Candidates+for+Alzheimer%E2%80%99s+Disease%2C+Enabled+by+J-Brain+Cargo%C2%AE+Technology+Platform/26658824.html <p class="bwalignc"> <i>- Strategic partnership, announced in July 2025, utilizes JCR’s J-Brain Cargo® to develop a novel blood-brain barrier-penetrating therapy targeting a pathological driver of Alzheimer’s disease</i> </p><p class="bwalignc"> <i>- Option exercise puts Acumen’s Enhanced Brain Delivery (EBD™) program on track for IND filing in mid-2027</i> </p> <p> HYOGO, Japan--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fjcrpharm.com%2F&amp;esheet=54556000&amp;newsitemid=20260617134083&amp;lan=en-US&amp;anchor=JCR+Pharmaceuticals+Co.%2C+Ltd.&amp;index=1&amp;md5=fcae3009ac02737d9d40dc50df398793" shape="rect">JCR Pharmaceuticals Co., Ltd.</a> (TSE 4552; JCR), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced that Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) exercised its exclusive option to develop, manufacture, and commercialize, on a global basis, up to two candidates for development http://www.streetinsider.com/Press+Releases/JCR+Pharmaceuticals+Announces+That+Acumen+Pharmaceuticals+Has+Exercised+its+Exclusive+Option+to+Develop+Therapeutic+Candidates+for+Alzheimer%E2%80%99s+Disease%2C+Enabled+by+J-Brain+Cargo%C2%AE+Technology+Platform/26658824.html Wed, 17 Jun 2026 12:30:00 -0400 4552 A.06822034 ABOS O.05105781 O.20026344 O.47039291 http://www.streetinsider.com/Press+Releases/JCR+Pharmaceuticals+Announces+That+Acumen+Pharmaceuticals+Has+Exercised+its+Exclusive+Option+to+Develop+Therapeutic+Candidates+for+Alzheimer%E2%80%99s+Disease%2C+Enabled+by+J-Brain+Cargo%C2%AE+Technology+Platform/26658824.html <p class="bwalignc"> <i>- Strategic partnership, announced in July 2025, utilizes JCR’s J-Brain Cargo® to develop a novel blood-brain barrier-penetrating therapy targeting a pathological driver of Alzheimer’s disease</i> </p><p class="bwalignc"> <i>- Option exercise puts Acumen’s Enhanced Brain Delivery (EBD™) program on track for IND filing in mid-2027</i> </p> <p> HYOGO, Japan--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fjcrpharm.com%2F&amp;esheet=54556000&amp;newsitemid=20260617134083&amp;lan=en-US&amp;anchor=JCR+Pharmaceuticals+Co.%2C+Ltd.&amp;index=1&amp;md5=fcae3009ac02737d9d40dc50df398793" shape="rect">JCR Pharmaceuticals Co., Ltd.</a> (TSE 4552; JCR), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced that Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) exercised its exclusive option to develop, manufacture, and commercialize, on a global basis, up to two candidates for development http://www.streetinsider.com/Press+Releases/JCR+Pharmaceuticals+Announces+That+Acumen+Pharmaceuticals+Has+Exercised+its+Exclusive+Option+to+Develop+Therapeutic+Candidates+for+Alzheimer%E2%80%99s+Disease%2C+Enabled+by+J-Brain+Cargo%C2%AE+Technology+Platform/26658824.html Wed, 17 Jun 2026 12:30:00 -0400 4552 A.06822034 ABOS O.05105781 O.20026344 O.47039291 http://www.streetinsider.com/Press+Releases/JCR+Pharmaceuticals+Announces+That+Acumen+Pharmaceuticals+Has+Exercised+its+Exclusive+Option+to+Develop+Therapeutic+Candidates+for+Alzheimer%E2%80%99s+Disease%2C+Enabled+by+J-Brain+Cargo%C2%AE+Technology+Platform/26658824.html <p class="bwalignc"> <i>- Strategic partnership, announced in July 2025, utilizes JCR’s J-Brain Cargo® to develop a novel blood-brain barrier-penetrating therapy targeting a pathological driver of Alzheimer’s disease</i> </p><p class="bwalignc"> <i>- Option exercise puts Acumen’s Enhanced Brain Delivery (EBD™) program on track for IND filing in mid-2027</i> </p> <p> HYOGO, Japan--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fjcrpharm.com%2F&amp;esheet=54556000&amp;newsitemid=20260617134083&amp;lan=en-US&amp;anchor=JCR+Pharmaceuticals+Co.%2C+Ltd.&amp;index=1&amp;md5=fcae3009ac02737d9d40dc50df398793" shape="rect">JCR Pharmaceuticals Co., Ltd.</a> (TSE 4552; JCR), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced that Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) exercised its exclusive option to develop, manufacture, and commercialize, on a global basis, up to two candidates for development http://www.streetinsider.com/Press+Releases/JCR+Pharmaceuticals+Announces+That+Acumen+Pharmaceuticals+Has+Exercised+its+Exclusive+Option+to+Develop+Therapeutic+Candidates+for+Alzheimer%E2%80%99s+Disease%2C+Enabled+by+J-Brain+Cargo%C2%AE+Technology+Platform/26658824.html Wed, 17 Jun 2026 12:30:00 -0400 4552 A.06822034 ABOS O.05105781 O.20026344 O.47039291 http://www.streetinsider.com/Business+Wire/JCR+Pharmaceuticals+Announces+That+Acumen+Pharmaceuticals+Has+Exercised+its+Exclusive+Option+to+Develop+Therapeutic+Candidates+for+Alzheimer%E2%80%99s+Disease%2C+Enabled+by+J-Brain+Cargo%C2%AE+Technology+Platform/26658824.html <p class="bwalignc"> <i>- Strategic partnership, announced in July 2025, utilizes JCR’s J-Brain Cargo® to develop a novel blood-brain barrier-penetrating therapy targeting a pathological driver of Alzheimer’s disease</i> </p><p class="bwalignc"> <i>- Option exercise puts Acumen’s Enhanced Brain Delivery (EBD™) program on track for IND filing in mid-2027</i> </p> <p> HYOGO, Japan--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fjcrpharm.com%2F&amp;esheet=54556000&amp;newsitemid=20260617134083&amp;lan=en-US&amp;anchor=JCR+Pharmaceuticals+Co.%2C+Ltd.&amp;index=1&amp;md5=fcae3009ac02737d9d40dc50df398793" shape="rect">JCR Pharmaceuticals Co., Ltd.</a> (TSE 4552; JCR), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced that Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) exercised its exclusive option to develop, manufacture, and commercialize, on a global basis, up to two candidates for development http://www.streetinsider.com/Business+Wire/JCR+Pharmaceuticals+Announces+That+Acumen+Pharmaceuticals+Has+Exercised+its+Exclusive+Option+to+Develop+Therapeutic+Candidates+for+Alzheimer%E2%80%99s+Disease%2C+Enabled+by+J-Brain+Cargo%C2%AE+Technology+Platform/26658824.html Wed, 17 Jun 2026 12:30:00 -0400 4552 A.06822034 ABOS O.05105781 O.20026344 O.47039291 http://www.streetinsider.com/Business+Wire/JCR+Pharmaceuticals+Announces+That+Acumen+Pharmaceuticals+Has+Exercised+its+Exclusive+Option+to+Develop+Therapeutic+Candidates+for+Alzheimer%E2%80%99s+Disease%2C+Enabled+by+J-Brain+Cargo%C2%AE+Technology+Platform/26658824.html <p class="bwalignc"> <i>- Strategic partnership, announced in July 2025, utilizes JCR’s J-Brain Cargo® to develop a novel blood-brain barrier-penetrating therapy targeting a pathological driver of Alzheimer’s disease</i> </p><p class="bwalignc"> <i>- Option exercise puts Acumen’s Enhanced Brain Delivery (EBD™) program on track for IND filing in mid-2027</i> </p> <p> HYOGO, Japan--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fjcrpharm.com%2F&amp;esheet=54556000&amp;newsitemid=20260617134083&amp;lan=en-US&amp;anchor=JCR+Pharmaceuticals+Co.%2C+Ltd.&amp;index=1&amp;md5=fcae3009ac02737d9d40dc50df398793" shape="rect">JCR Pharmaceuticals Co., Ltd.</a> (TSE 4552; JCR), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced that Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) exercised its exclusive option to develop, manufacture, and commercialize, on a global basis, up to two candidates for development http://www.streetinsider.com/Business+Wire/JCR+Pharmaceuticals+Announces+That+Acumen+Pharmaceuticals+Has+Exercised+its+Exclusive+Option+to+Develop+Therapeutic+Candidates+for+Alzheimer%E2%80%99s+Disease%2C+Enabled+by+J-Brain+Cargo%C2%AE+Technology+Platform/26658824.html Wed, 17 Jun 2026 12:30:00 -0400 4552 A.06822034 ABOS O.05105781 O.20026344 O.47039291 http://www.streetinsider.com/Business+Wire/JCR+Pharmaceuticals+Announces+That+Acumen+Pharmaceuticals+Has+Exercised+its+Exclusive+Option+to+Develop+Therapeutic+Candidates+for+Alzheimer%E2%80%99s+Disease%2C+Enabled+by+J-Brain+Cargo%C2%AE+Technology+Platform/26658824.html <p class="bwalignc"> <i>- Strategic partnership, announced in July 2025, utilizes JCR’s J-Brain Cargo® to develop a novel blood-brain barrier-penetrating therapy targeting a pathological driver of Alzheimer’s disease</i> </p><p class="bwalignc"> <i>- Option exercise puts Acumen’s Enhanced Brain Delivery (EBD™) program on track for IND filing in mid-2027</i> </p> <p> HYOGO, Japan--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fjcrpharm.com%2F&amp;esheet=54556000&amp;newsitemid=20260617134083&amp;lan=en-US&amp;anchor=JCR+Pharmaceuticals+Co.%2C+Ltd.&amp;index=1&amp;md5=fcae3009ac02737d9d40dc50df398793" shape="rect">JCR Pharmaceuticals Co., Ltd.</a> (TSE 4552; JCR), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced that Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) exercised its exclusive option to develop, manufacture, and commercialize, on a global basis, up to two candidates for development http://www.streetinsider.com/Business+Wire/JCR+Pharmaceuticals+Announces+That+Acumen+Pharmaceuticals+Has+Exercised+its+Exclusive+Option+to+Develop+Therapeutic+Candidates+for+Alzheimer%E2%80%99s+Disease%2C+Enabled+by+J-Brain+Cargo%C2%AE+Technology+Platform/26658824.html Wed, 17 Jun 2026 12:30:00 -0400 4552 A.06822034 ABOS O.05105781 O.20026344 O.47039291 http://www.streetinsider.com/Business+Wire/JCR+Pharmaceuticals+Announces+That+Acumen+Pharmaceuticals+Has+Exercised+its+Exclusive+Option+to+Develop+Therapeutic+Candidates+for+Alzheimer%E2%80%99s+Disease%2C+Enabled+by+J-Brain+Cargo%C2%AE+Technology+Platform/26658824.html <p class="bwalignc"> <i>- Strategic partnership, announced in July 2025, utilizes JCR’s J-Brain Cargo® to develop a novel blood-brain barrier-penetrating therapy targeting a pathological driver of Alzheimer’s disease</i> </p><p class="bwalignc"> <i>- Option exercise puts Acumen’s Enhanced Brain Delivery (EBD™) program on track for IND filing in mid-2027</i> </p> <p> HYOGO, Japan--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fjcrpharm.com%2F&amp;esheet=54556000&amp;newsitemid=20260617134083&amp;lan=en-US&amp;anchor=JCR+Pharmaceuticals+Co.%2C+Ltd.&amp;index=1&amp;md5=fcae3009ac02737d9d40dc50df398793" shape="rect">JCR Pharmaceuticals Co., Ltd.</a> (TSE 4552; JCR), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced that Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) exercised its exclusive option to develop, manufacture, and commercialize, on a global basis, up to two candidates for development http://www.streetinsider.com/Business+Wire/JCR+Pharmaceuticals+Announces+That+Acumen+Pharmaceuticals+Has+Exercised+its+Exclusive+Option+to+Develop+Therapeutic+Candidates+for+Alzheimer%E2%80%99s+Disease%2C+Enabled+by+J-Brain+Cargo%C2%AE+Technology+Platform/26658824.html Wed, 17 Jun 2026 12:30:00 -0400 4552 A.06822034 ABOS O.05105781 O.20026344 O.47039291 http://www.streetinsider.com/Business+Wire/JCR+Pharmaceuticals+Announces+That+Acumen+Pharmaceuticals+Has+Exercised+its+Exclusive+Option+to+Develop+Therapeutic+Candidates+for+Alzheimer%E2%80%99s+Disease%2C+Enabled+by+J-Brain+Cargo%C2%AE+Technology+Platform/26658824.html <p class="bwalignc"> <i>- Strategic partnership, announced in July 2025, utilizes JCR’s J-Brain Cargo® to develop a novel blood-brain barrier-penetrating therapy targeting a pathological driver of Alzheimer’s disease</i> </p><p class="bwalignc"> <i>- Option exercise puts Acumen’s Enhanced Brain Delivery (EBD™) program on track for IND filing in mid-2027</i> </p> <p> HYOGO, Japan--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fjcrpharm.com%2F&amp;esheet=54556000&amp;newsitemid=20260617134083&amp;lan=en-US&amp;anchor=JCR+Pharmaceuticals+Co.%2C+Ltd.&amp;index=1&amp;md5=fcae3009ac02737d9d40dc50df398793" shape="rect">JCR Pharmaceuticals Co., Ltd.</a> (TSE 4552; JCR), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced that Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) exercised its exclusive option to develop, manufacture, and commercialize, on a global basis, up to two candidates for development http://www.streetinsider.com/Business+Wire/JCR+Pharmaceuticals+Announces+That+Acumen+Pharmaceuticals+Has+Exercised+its+Exclusive+Option+to+Develop+Therapeutic+Candidates+for+Alzheimer%E2%80%99s+Disease%2C+Enabled+by+J-Brain+Cargo%C2%AE+Technology+Platform/26658824.html Wed, 17 Jun 2026 12:30:00 -0400 4552 A.06822034 ABOS O.05105781 O.20026344 O.47039291 http://www.streetinsider.com/Business+Wire/JCR+Pharmaceuticals+Announces+That+Acumen+Pharmaceuticals+Has+Exercised+its+Exclusive+Option+to+Develop+Therapeutic+Candidates+for+Alzheimer%E2%80%99s+Disease%2C+Enabled+by+J-Brain+Cargo%C2%AE+Technology+Platform/26658824.html <p class="bwalignc"> <i>- Strategic partnership, announced in July 2025, utilizes JCR’s J-Brain Cargo® to develop a novel blood-brain barrier-penetrating therapy targeting a pathological driver of Alzheimer’s disease</i> </p><p class="bwalignc"> <i>- Option exercise puts Acumen’s Enhanced Brain Delivery (EBD™) program on track for IND filing in mid-2027</i> </p> <p> HYOGO, Japan--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fjcrpharm.com%2F&amp;esheet=54556000&amp;newsitemid=20260617134083&amp;lan=en-US&amp;anchor=JCR+Pharmaceuticals+Co.%2C+Ltd.&amp;index=1&amp;md5=fcae3009ac02737d9d40dc50df398793" shape="rect">JCR Pharmaceuticals Co., Ltd.</a> (TSE 4552; JCR), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced that Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) exercised its exclusive option to develop, manufacture, and commercialize, on a global basis, up to two candidates for development http://www.streetinsider.com/Business+Wire/JCR+Pharmaceuticals+Announces+That+Acumen+Pharmaceuticals+Has+Exercised+its+Exclusive+Option+to+Develop+Therapeutic+Candidates+for+Alzheimer%E2%80%99s+Disease%2C+Enabled+by+J-Brain+Cargo%C2%AE+Technology+Platform/26658824.html Wed, 17 Jun 2026 12:30:00 -0400 4552 A.06822034 ABOS O.05105781 O.20026344 O.47039291 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Acumen+Pharmaceuticals%2C++++++++++++++++Filed+by%3A+Porter+Derrell/26655120.html si-local-file:///var/storage/secattach/20260616/26655120.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Acumen+Pharmaceuticals%2C++++++++++++++++Filed+by%3A+Porter+Derrell/26655120.html Tue, 16 Jun 2026 17:04:00 -0400 ABOS O.47039291 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Acumen+Pharmaceuticals%2C++++++++++++++++Filed+by%3A+Porter+Derrell/26655120.html si-local-file:///var/storage/secattach/20260616/26655120.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Acumen+Pharmaceuticals%2C++++++++++++++++Filed+by%3A+Porter+Derrell/26655120.html Tue, 16 Jun 2026 17:04:00 -0400 ABOS O.47039291 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Acumen+Pharmaceuticals%2C+++For%3A+Jun+12/26650485.html si-local-file:///var/storage/secattach/20260616/26650485.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Acumen+Pharmaceuticals%2C+++For%3A+Jun+12/26650485.html Tue, 16 Jun 2026 07:34:00 -0400 ABOS O.47039291 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Acumen+Pharmaceuticals%2C+++For%3A+Jun+12/26650485.html si-local-file:///var/storage/secattach/20260616/26650485.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Acumen+Pharmaceuticals%2C+++For%3A+Jun+12/26650485.html Tue, 16 Jun 2026 07:34:00 -0400 ABOS O.47039291 http://www.streetinsider.com/Corporate+News/ACUMEN+Pharmaceuticals+nominates+two+Alzheimer%27s+drug+candidates/26650474.html <p>Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) announced the nomination of two development candidates, ACU301 and ACU401, in its Enhanced Brain Delivery (EBD) program for the treatment of Alzheimer's disease.</p><p>The nominations follow Acumen's exercise of an option under its license agreement with JCR Pharmaceuticals. The candidates combine Acumen's amyloid beta oligomer (AβO)-selective antibody technology with JCR's J-Brain Cargo® blood-brain barrier-penetrating platform, which uses transferrin-receptor-targeting receptor-mediated transcytosis to deliver therapeutics to the central nervous system.</p><p>ACU301 is a bispecific antibody derived from sabirnetug, Acumen's existing clinical-stage antibody candidate. ACU401 is based on ACU234, described as a next-generation AβO-selective antibody. Both candidates are intended for http://www.streetinsider.com/Corporate+News/ACUMEN+Pharmaceuticals+nominates+two+Alzheimer%27s+drug+candidates/26650474.html Tue, 16 Jun 2026 07:32:04 -0400 ABOS http://www.streetinsider.com/Press+Releases/Acumen+Pharmaceuticals+Announces+Nomination+of+Two+Enhanced+Brain+Delivery%E2%84%A2+%28EBD%E2%84%A2%29+Development+Candidates+for+the+Treatment+of+Alzheimer%E2%80%99s+Disease/26650425.html <ul type="disc"><li style="margin-bottom:8pt;">ACU301 and ACU401 were nominated in the EBD program as part of the exercise of Acumen’s option under its license agreement with JCR Pharmaceuticals</li><li style="margin-bottom:8pt;">EBD technology represents the only anti-amyloid oligomer program combining a validated blood-brain barrier-penetrating technology with a therapeutic antibody tested in the clinic</li><li style="margin-bottom:8pt;">Acumen’s EBD candidates are designed to achieve higher brain penetration with potential for improved safety compared to native antibodies and delivered in a stable, low volume subcutaneous administration format</li><li style="margin-bottom:8pt;">Investigational New Drug (IND)-enabling activities are ongoing to support IND submission in mid-2027</li></ul> <p align="justify">NEWTON, Mass., June 16, 2026 (GLOBE http://www.streetinsider.com/Press+Releases/Acumen+Pharmaceuticals+Announces+Nomination+of+Two+Enhanced+Brain+Delivery%E2%84%A2+%28EBD%E2%84%A2%29+Development+Candidates+for+the+Treatment+of+Alzheimer%E2%80%99s+Disease/26650425.html Tue, 16 Jun 2026 07:30:00 -0400 ABOS http://www.streetinsider.com/Globe+Newswire/Acumen+Pharmaceuticals+Announces+Nomination+of+Two+Enhanced+Brain+Delivery%E2%84%A2+%28EBD%E2%84%A2%29+Development+Candidates+for+the+Treatment+of+Alzheimer%E2%80%99s+Disease/26650425.html <ul type="disc"><li style="margin-bottom:8pt;">ACU301 and ACU401 were nominated in the EBD program as part of the exercise of Acumen’s option under its license agreement with JCR Pharmaceuticals</li><li style="margin-bottom:8pt;">EBD technology represents the only anti-amyloid oligomer program combining a validated blood-brain barrier-penetrating technology with a therapeutic antibody tested in the clinic</li><li style="margin-bottom:8pt;">Acumen’s EBD candidates are designed to achieve higher brain penetration with potential for improved safety compared to native antibodies and delivered in a stable, low volume subcutaneous administration format</li><li style="margin-bottom:8pt;">Investigational New Drug (IND)-enabling activities are ongoing to support IND submission in mid-2027</li></ul> <p align="justify">NEWTON, Mass., June 16, 2026 (GLOBE http://www.streetinsider.com/Globe+Newswire/Acumen+Pharmaceuticals+Announces+Nomination+of+Two+Enhanced+Brain+Delivery%E2%84%A2+%28EBD%E2%84%A2%29+Development+Candidates+for+the+Treatment+of+Alzheimer%E2%80%99s+Disease/26650425.html Tue, 16 Jun 2026 07:30:00 -0400 ABOS http://www.streetinsider.com/SEC+Filings/Form++144++++++++Acumen+Pharmaceuticals%2C++++++++++++++++Filed+by%3A+Porter+Derrell/26648916.html si-local-file:///var/storage/secattach/20260615/26648916.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Acumen+Pharmaceuticals%2C++++++++++++++++Filed+by%3A+Porter+Derrell/26648916.html Mon, 15 Jun 2026 18:32:00 -0400 ABOS O.47039291 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Acumen+Pharmaceuticals%2C++++++++++++++++Filed+by%3A+Porter+Derrell/26648916.html si-local-file:///var/storage/secattach/20260615/26648916.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Acumen+Pharmaceuticals%2C++++++++++++++++Filed+by%3A+Porter+Derrell/26648916.html Mon, 15 Jun 2026 18:32:00 -0400 ABOS O.47039291